Compare Wahana Inti Makmur Tbk. (NASI) vs Organon Pharma Indonesia Tbk. (SCPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Wahana Inti Makmur Tbk. vs Organon Pharma Indonesia Tbk. — how do they compare? Wahana Inti Makmur Tbk. trades at Rp165 (market cap 131.61B, 4.22M 24h volume), while Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B). The key difference: Wahana Inti Makmur Tbk. is the larger of the two by market cap. Which is the better fit depends on your goals.
| NASI | SCPI | |
|---|---|---|
Market Cap | 131.61B | 104.4B |
Volume | 4.22M | — |
Lot | 42.25K | — |
Turnover | 683.98M | — |
Average Price | 161.9 | — |
Value | 683.98M | — |
Indicative Equilibrium Price | 165 | — |
Indicative Equilibrium Volume | 1.61K | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Wahana Inti Makmur Tbk.
PT Wahana Inti Makmur Tbk (the Company) is established based on Deed of Establishment No. 02 dated February 14, 2015 made by Dr. Tio Jeffrens Maranella, S.H., Notary in Jakarta. The Company started its commercial operations in February 2015.
Read more on NASI →About Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →
